Modakafusp alfa is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Modakafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Modakafusp alfa overview
TAK-573 is under development for the treatment of relapsed/refractory multiple myeloma, metastatic solid tumors including metastatic cutaneous melanoma. It is administered through intravenous route. It consists of CD38-targeted IgG4 fused with attenuated interferon (IFN) alpha for tumor-specificity. The therapeutic candidate is a monoclonal antibody fusion protein and it acts by targeting cells expressing CD38. The drug candidate was also under development for the treatment of metastatic castrate-resistant prostate cancer, non-small cell lung cancer, head and neck cancer, pancreatic ductal adenocarcinoma, triple negative breast cancer and microsatellite stable colon cancer.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Modakafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.